Nektar Therapeutics ( NKTR) on Monday named Howard W. Robin as its new president and chief executive, effective Jan. 15.

Robin, 53, replaces Howard Chess, who has been acting president and CEO since March following the retirement of Ajit Gill. Chess will remain as chairman of the medical-device company.

Nektar is known best as Pfizer's ( PFE) partner for the inhaled insulin Exubera.

For the past five years, Robin had been president and CEO of Sirna Therapeutics, a biotechnology company that was just purchased by Merck ( MRK).

Before joing Sirna, Robin spent 20 years at Berlex Laboratories, the U.S. subsidiary of the German drugmaker Schering AG.

More from Stocks

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Video: Here Is Why Carvana Isn't Worried About Amazon

Video: Here Is Why Carvana Isn't Worried About Amazon

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat